We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology
News

ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology

ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology
News

ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ITI Life Sciences Seeks to Fund Innovative R&D Programme in Synthetic Biology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ITI Life Sciences, the publicly funded innovation group, issues a Call for Expressions of Interest from organizations or individuals with expertise in Synthetic Biology techniques that could be applied to Gene & Genome Synthesis and Assembly.

ITI Life Sciences’ is seeking to commission a new R&D programme to develop technologies that can be further developed to create high-value commercial products. Typically, R&D programmes will receive in the range of £2–5 million (US$4–10 million) over an anticipated term of 18–36 months, and are expected to lead to the creation of centers of research excellence in Scotland.

Synthetic Biology is a highly promising new area of biotechnology that merges biology with engineering to create new microorganisms programmed to perform complex biological processes for specific industrial applications. It is a significant advance on current genetic engineering technologies owing to the level of both engineering involved and the controllability of the process.

ITI Life Sciences’ market and technology analysis process (foresighting) has concluded that such applications are expected to address market needs in a variety of sectors of high commercial and societal value, ranging from bioenergy, chemical synthesis, drug and vaccine development, biosensor development and tissue engineering. As such, Synthetic Biology is attracting considerable interest from academia, industry and the financial community, and major opportunities exist in the development of enabling technologies to drive this new area forward.

Advertisement